Your browser is no longer supported. Please, upgrade your browser.
KNSA Kiniksa Pharmaceuticals, Ltd. daily Stock Chart
KNSA [NASD]
Kiniksa Pharmaceuticals, Ltd.
Index- P/E- EPS (ttm)-2.20 Insider Own6.96% Shs Outstand57.91M Perf Week-15.86%
Market Cap1.19B Forward P/E- EPS next Y-2.58 Insider Trans-6.76% Shs Float29.31M Perf Month10.02%
Income-122.70M PEG- EPS next Q-0.61 Inst Own67.80% Short Float11.25% Perf Quarter-18.74%
Sales- P/S- EPS this Y-43.60% Inst Trans0.08% Short Ratio7.64 Perf Half Y-13.16%
Book/sh4.32 P/B4.02 EPS next Y-10.30% ROA-47.50% Target Price- Perf Year193.07%
Cash/sh3.69 P/C4.70 EPS next 5Y- ROE-52.60% 52W Range5.30 - 28.67 Perf YTD56.87%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.48% Beta-
Dividend %- Quick Ratio12.90 Sales past 5Y- Gross Margin- 52W Low227.36% ATR1.12
Employees135 Current Ratio12.90 Sales Q/Q- Oper. Margin- RSI (14)46.49 Volatility5.82% 6.56%
OptionableYes Debt/Eq0.00 EPS Q/Q5.20% Profit Margin- Rel Volume0.64 Prev Close18.20
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume431.38K Price17.35
Recom1.60 SMA20-1.26% SMA500.39% SMA200-6.36% Volume274,379 Change-4.67%
Jun-29-20Reiterated BofA Securities Buy $25 → $40
Apr-01-20Initiated BofA/Merrill Buy $25
Mar-11-19Initiated Barclays Overweight $26
Dec-12-18Reiterated Wedbush Outperform $31 → $33
Jun-19-18Initiated JMP Securities Mkt Outperform $33
Oct-14-20 09:54PM  
Oct-07-20 10:14AM  
Oct-06-20 08:00AM  
Sep-24-20 04:12PM  
Sep-21-20 08:00AM  
Sep-15-20 08:00AM  
Sep-09-20 04:01PM  
Aug-31-20 08:00AM  
Aug-04-20 08:00AM  
Jul-30-20 07:30AM  
Jul-28-20 03:42PM  
Jul-21-20 09:55PM  
Jul-20-20 04:07PM  
Jul-16-20 07:30AM  
Jul-08-20 12:53PM  
Jul-05-20 11:03PM  
Jun-30-20 09:56AM  
09:35AM  
Jun-29-20 03:47PM  
10:48AM  
08:09AM  
07:15AM  
Jun-17-20 08:00AM  
Jun-12-20 10:43AM  
Jun-10-20 08:00AM  
Jun-08-20 08:00AM  
Jun-04-20 08:00AM  
May-29-20 08:30AM  
May-22-20 08:56AM  
May-18-20 04:01PM  
May-13-20 11:12PM  
05:12PM  
May-11-20 07:30AM  
May-06-20 11:43AM  
Apr-28-20 07:30AM  
Apr-22-20 08:00AM  
Apr-08-20 11:30AM  
Apr-06-20 07:45PM  
08:29AM  
Apr-01-20 09:04AM  
Mar-31-20 08:15AM  
Mar-30-20 07:30AM  
Feb-26-20 07:30AM  
Feb-11-20 09:12AM  
Feb-05-20 09:21AM  
Jan-13-20 08:00AM  
Dec-19-19 10:13AM  
Dec-18-19 02:27PM  
Dec-16-19 07:29AM  
Dec-12-19 09:59AM  
Dec-11-19 09:47AM  
08:30AM  
Dec-10-19 08:00AM  
Dec-07-19 07:07AM  
Nov-21-19 10:22AM  
Nov-20-19 04:01PM  
08:00AM  
Nov-16-19 12:00PM  
Nov-12-19 04:01PM  
Nov-01-19 10:55AM  
Oct-28-19 04:01PM  
Oct-08-19 04:48AM  
Sep-19-19 04:01PM  
Aug-19-19 07:30AM  
Aug-12-19 04:02PM  
04:01PM  
Aug-06-19 07:30AM  
Aug-05-19 07:30AM  
Jun-29-19 06:17PM  
Jun-12-19 07:30AM  
Jun-10-19 11:26AM  
May-30-19 04:01PM  
May-29-19 04:01PM  
May-16-19 07:30AM  
May-13-19 07:30AM  
May-02-19 07:30AM  
Apr-29-19 02:55PM  
Apr-23-19 06:00AM  
Apr-17-19 04:25PM  
Apr-08-19 04:01PM  
Mar-18-19 07:30AM  
Mar-07-19 07:30AM  
Feb-28-19 07:30AM  
Feb-26-19 07:30AM  
Jan-31-19 08:57AM  
Jan-29-19 07:25AM  
Jan-28-19 05:23PM  
Jan-03-19 07:30AM  
Dec-27-18 08:14AM  
Dec-17-18 08:36AM  
Dec-11-18 07:30AM  
Dec-06-18 08:00AM  
Nov-15-18 07:35AM  
Nov-01-18 08:00AM  
Sep-15-18 08:00AM  
Aug-29-18 07:30AM  
Aug-28-18 04:01PM  
Aug-06-18 07:30AM  
Aug-02-18 04:01PM  
Jun-25-18 07:00AM  
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel Sanj KChairman & CEOOct 12Option Exercise1.59150,700239,613150,700Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 12Sale21.0299,3302,087,917112,570Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 12Sale21.02150,7003,167,7140Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 09Option Exercise1.598721,386872Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 09Sale21.0067014,070211,900Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 09Sale21.0087218,3120Oct 14 05:22 PM
Beetham Thomas W.EVP & Chief Legal OfficerJul 01Sale25.3729,589750,6780Jul 02 04:13 PM
Beetham Thomas W.EVP & Chief Legal OfficerJun 10Option Exercise1.5913,75221,86643,341Jun 12 05:50 PM
Beetham Thomas W.EVP & Chief Legal OfficerJun 10Sale25.0713,752344,76329,589Jun 12 05:50 PM
Beetham Thomas W.EVP & Chief Legal OfficerApr 21Sale19.892,51850,09229,589Apr 22 05:39 PM
Beetham Thomas W.EVP & Chief Legal OfficerApr 20Sale19.0647,423903,88232,107Apr 22 05:39 PM
Patel Sanj KChairman & CEOMar 06Sale20.0033,115662,300212,570Mar 10 05:33 PM
Paolini John F.SVP & Chief Medical OfficerFeb 27Option Exercise1.8612,00022,32030,000Mar 02 05:48 PM
Paolini John F.SVP & Chief Medical OfficerFeb 20Option Exercise3.809,80337,25127,803Feb 21 04:57 PM
Paolini John F.SVP & Chief Medical OfficerFeb 20Sale18.969,803185,83218,000Feb 21 04:57 PM
Paolini John F.SVP & Chief Medical OfficerFeb 19Option Exercise3.8022,47785,41340,477Feb 21 04:57 PM
Paolini John F.SVP & Chief Medical OfficerFeb 19Sale18.2722,477410,65518,000Feb 21 04:57 PM
Paolini John F.SVP & Chief Medical OfficerFeb 14Option Exercise3.801,0393,94819,039Feb 18 06:05 PM
Beetham Thomas W.EVP & Chief Legal OfficerFeb 14Sale18.58591,09679,530Feb 19 05:24 PM
Paolini John F.SVP & Chief Medical OfficerFeb 14Sale18.331,03919,04518,000Feb 18 06:05 PM
Paolini John F.SVP & Chief Medical OfficerFeb 13Option Exercise3.8010,27739,05328,277Feb 18 06:05 PM
Paolini John F.SVP & Chief Medical OfficerFeb 13Sale18.2910,277187,96618,000Feb 18 06:05 PM
Paolini John F.SVP & Chief Medical OfficerDec 05Option Exercise1.868,00014,8808,000Dec 09 05:57 PM